TimeTech's Global Expansion, the EuroHealth Acquisition and Financing Strategy

E3 + P3 + F3 · Global Strategy · M&A Due Diligence · Risk Governance · EPS, Dilution and Capital Structure

Level：Strategic Duration：about 180 min Points available：16 Agent roles：8

A self-authored, Strategic level-style strategic simulation set in a fictional post-IPO scenario: TimeTech is pursuing global growth, and as its Chief Strategy Officer you gather evidence, separate facts from planning assumptions, compare strategic paths, and put a pausable, reviewable and exitable recommendation to the CEO and board.

Start learning

The question

For 2029, management-basis sales revenue is USD 200 million and net profit is USD 30 million. Within the case, 20 million ordinary shares are in issue and the observed share price is USD 50 per share; the resulting USD 1 billion is merely a market-capitalisation control figure for teaching purposes and must not be treated as real market data.

Company background

TimeTech Ltd. is a fictional smart health wearables company. In this case it is assumed to have completed a hypothetical IPO in 2028, raising USD 200 million; these details belong to the case scenario only and are not the listing record, market quotes or official examination materials of any real company.

Techniques

战略与财务技术分析商业判断与战略选择风险、治理与实施利益相关者与领导沟通

Who it suits

Recommended for learners who have completed E3, P3 and F3 and are undertaking integrated Strategic-level training. It focuses on corporate-level strategic choice, cross-border M&A, risk governance, financing structure, board communication and conditional decision-making.

All courses

Home